Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
9-ING-41 with chemotherapy in advanced sarcoma
NCT05116800Phase 2Withdrawn
- Sponsor
- Brown University
- Start
- Mar 2022
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of elraglusib in soft tissue sarcoma (STS) and bone sarcoma (2 arms), sponsored by Brown University. Primary endpoint: Disease Control Rate at 24 weeks. Planned start Mar 2022; status: withdrawn.
02
Drugs
elraglusib
03
Conditions
soft tissue sarcoma (STS)bone sarcoma
Beyond the preview
Go deeper on NCT05116800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05116800.